RxDoctor Payments Data

Nidal Hasan, MD

Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1326024134

Payments from drug & device makers

$830in general payments, 2019–2025

Across 50 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$224
  • Novo Nordisk$215
  • Amgen$159
  • Bayer$56
  • Boehringer Ingelheim$49
  • AstraZeneca$31
  • plus $97 from 6 others

What the payments were for

  • Food & beverage$71386%
  • Education$11714%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$830 in reported general payments places this provider in the 50th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois

Medicare billing

Part B allowed, 2024
$154,089
Medicare patients
231
Services billed
1,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide378$448,607
MounjaroTirzepatide118$165,777
FarxigaDapagliflozin Propanediol100$111,264
AfrezzaInsulin Regular, Human26$84,415
RybelsusSemaglutide42$64,646
JanuviaSitagliptin Phosphate60$55,787
TrulicityDulaglutide38$48,757
JardianceEmpagliflozin38$43,556
Tresiba Flextouch U-200Insulin Degludec21$32,395
TradjentaLinagliptin27$28,806
Fiasp FlextouchInsulin Aspart (Niacinamide)19$16,606
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp42$15,899
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro24$14,911
EliquisApixaban11$13,706
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$11,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$215$513,253420 claims
Lilly USA, LLCMounjaro, Trulicity$224$214,534156 claims
AstraZenecaFarxiga$31$111,264100 claims
Mannkind CorporationAfrezza$20$84,41526 claims
Boehringer IngelheimJardiance, Tradjenta$49$72,36265 claims
MerckJanuvia$12$55,78760 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

Other endocrinology, diabetes & metabolism in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →